Drug Discovery · Burlington, MA · Founded 2021 · Privately Held (backing)
Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. Hyku Biosciences is based in Burlington, MA and was founded in 2021. It was valued at $85 million at its seed round in Nov 2024, the last priced event on record. It has raised $70.6 million across 2 recorded rounds; the latest was a $6.6 million debt round in Dec 2025.
PMV mark · valuation
$85.0M
Oct 2026
Priced at
its seed round
Nov 2024
Total raised
$70.6M
Last round
Debt
Dec 2025
Cap table — not yet on record
Hyku Biosciences's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hyku Biosciences with a free account
·Watch Hyku Biosciences: the Monday email on marks, rounds and moves
Where does Hyku Biosciences's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Hyku Biosciences's 2 recorded funding rounds.
